Immunovant, inc. (HSAC)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18
Operating expenses:
Research and development (includes share-based compensation expense)

0

-

-

-

0

General and administrative (includes share-based compensation expense)

0

-

-

-

0

Total operating expenses

0

0

0

-

0

Interest expense

0

-

-

-

-

Other (income)/expense, net

0

-

-

-

0

Franchise taxes

-

0

0

-

-

Loss from operations

-

0

0

-

-

Interest income

-

0

0

-

-

Loss before provision for income taxes

0

0

0

-

0

Income tax expense

0

0

0

-

0

Operating costs

-

-

-

0

-

Net loss

-10,988

-8,541

0

0

0

Net loss per common share - basic and diluted

-0.28

0.05

0.02

0.00

-0.24

Weighted-average common shares outstanding – basic and diluted

41,035

11,500

11,500

2,500

36,735

Weighted average shares outstanding of non-redeemable common stock

-

2,875

2,875

-

-

Basic and diluted net loss per share, non-redeemable common stock

-

-0.14

-0.02

-

-